May 10, 2013
Endo Health Solutions Responds to FDA's Denial of OPANA® ER Citizen Petition and the Potential Approval of Additional Non-Abuse Deterrent Formulations of Generic Oxymorphone |
May 07, 2013
Endo Reports First Quarter Financial Results |
May 06, 2013
First Head-to-Head Study Shows GreenLight XPS® Laser Therapy Equally Safe And Effective With Faster Recovery As Commonly Used TURP For Treatment Of BPH |
Apr 15, 2013
Endo to Announce First Quarter 2013 Financial Results on May 7, 2013 |
Mar 05, 2013
Endo Health Solutions to Present at the Cowen and Company 33rd Annual Health Care Conference |
Feb 28, 2013
Endo Reports Fourth Quarter Financial Results And Reaffirms 2013 Financial Guidance |
Feb 25, 2013
Rajiv De Silva Named President and CEO of Endo Health Solutions |
Feb 13, 2013
Endo to Announce Fourth Quarter 2012 Financial Results on February 28, 2013 |
Jan 03, 2013
Endo Health Solutions Reaffirms 2012 Adjusted Earnings Per Share Outlook and Provides 2013 Financial Guidance |
Dec 19, 2012
Endo Health Solutions Comments on Dismissal of Suit Against FDA |
Dec 12, 2012
Endo Health Solutions Announces CEO Transition Plan |
Dec 11, 2012
Endo Health Solutions Launches 7.5mg and 15mg strengths of Reformulated, Designed to be Crush-Resistant, OPANA® ER |
Dec 06, 2012
Qualitest Issues Voluntary, Nationwide Recall of 101 Lots of Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10 mg/500 mg Due to the Potential for Oversized Tablets |
Nov 30, 2012
Endo Health Solutions Sues FDA to Protect Consumers from Non-Tamper Resistant Oxymorphone |
Nov 13, 2012
Endo Health Solutions Supplements Citizen Petition With Preliminary Data Showing a 59% Drop in Abuse of the Reformulated, Designed to be Crush-Resistant, OPANA® ER |
Nov 08, 2012
Endo Health Solutions to Present at 2012 Annual Credit Suisse Healthcare Conference |
Nov 07, 2012
Endo Health Solutions to Present at Jefferies 2012 Global Healthcare Conference |
Nov 05, 2012
Endo Reports Third Quarter Financial Results And Updates 2012 Financial Guidance |
Nov 02, 2012
HealthTronics Launches New Line Of Slimline Cryoprobes For Use With Its Endocare® Cryocare® Systems |
Oct 22, 2012
Endo to Announce Third Quarter 2012 Financial Results on Nov. 5, 2012 |
Oct 04, 2012
Endo Health Solutions Will Detail Long-Term Strategy At 2012 Investor Day |
Sep 28, 2012
Endo Health Solutions Appoints Jill D. Smith To Board of Directors |
Sep 28, 2012
Endo Health Solutions to Host Investor Day on Oct. 4, 2012, in New York City |
Sep 26, 2012
Endo Health Solutions Announces Receipt of Paragraph IV Certifications for OPANA® ER |
Sep 10, 2012
Qualitest Issues Voluntary, Nationwide Recall for One Lot of Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10 mg/500 mg Due to the Potential for Oversized Tablets |
Sep 06, 2012
Endo Pharmaceuticals Announces Reformulated Version of OPANA® ER with INTAC® Technology Designed to be Crush-Resistant Accounts for more than 90 Percent of OPANA ER Total Prescription Volume |
Sep 05, 2012
Endo Health Solutions to Present at UBS 2012 Global Life Sciences Conference |
Aug 23, 2012
Statement on FDA Decision Regarding Endo Citizen Petition and Approval of a Generic Formulation of LIDODERM® |
Aug 21, 2012
American Medical Systems' New MoXy® Fiber Delivers Over 50 Percent More Energy |
Aug 21, 2012
Endo Health Solutions to Present at Stifel Nicolaus 2012 Healthcare Conference |
Aug 07, 2012
Endo Reports Second Quarter Financial Results and Updates 2012 Financial Guidance |
Aug 07, 2012
Endo Health Solutions Announces Authorization of $450 Million Share Repurchase Program |
Aug 06, 2012
Qualitest Launches Generic Singulair® |
Aug 02, 2012
BioDelivery Sciences and Endo Health Solutions Announce Initiation of Enrollment in the Phase 3 Program for BEMA Buprenorphine for Chronic Pain |
Jul 30, 2012
Endo to Announce Second Quarter 2012 Financial Results on August 7, 2012 |
Jul 25, 2012
Qualitest Receives FDA Approval for Levetiracetam Extended-Release Tablets, 500mg and 750mg |
Jul 18, 2012
Endo Health Solutions Names New President of American Medical Systems |
Jun 14, 2012
Endo Completes Transition of OPANA® ER Franchise to New Formulation Designed to be Crush Resistant |
Jun 07, 2012
American Medical Systems and Allergan Sign Agreement for JetTouch™/BOTOX® Co-Development Program |
May 30, 2012
Endo Announces Resolution of Patent Litigation with Watson Pharmaceuticals Related to Lidoderm(R) |
May 25, 2012
Endo Health Solutions Inc. to Present at the Goldman Sachs 33rd Annual Global |
May 25, 2012
Endo Health Solutions Inc. to Present at Jefferies 2012 Global Healthcare |
May 23, 2012
Endo Health Solutions Inc. Announced as New Name for Endo Pharmaceuticals Holdings Inc. |
May 04, 2012
Endo to Present at Bank of America Merrill Lynch 2012 Health Care Conference |
May 01, 2012
Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel |
Apr 17, 2012
Endo Pharmaceuticals to Announce First Quarter 2012 Financial Results on May 1, 2012 |
Apr 12, 2012
Qualitest Pharmaceuticals Receives FDA Approval for Levetiracetam Oral Solution, 100 mg/mL |
Mar 29, 2012
Endo Announces Departure of American Medical Systems President |
Mar 22, 2012
Endo Acquires Johnson Matthey's Oxymorphone Patent |
Mar 13, 2012
Endo Files Amended Citizen Petition Seeking Public FDA Resolution of Several Safety and Efficacy Issues Prior to Approval of a Generic Formulation of LIDODERM® |
Mar 01, 2012
Endo Pharmaceuticals Announces Proposal to Change Name of Parent Company and Rebrands Enterprise: Revealing an Innovative Corporate Structure Dedicated to Redefining Healthcare Value |
Feb 24, 2012
Endo Pharmaceuticals Reports Strong Fourth Quarter Financial Results; Provides 2012 Financial Guidance |
Feb 22, 2012
Endo Pharmaceuticals to Present at Cowen & Co. 32nd Annual Health Care Conference |
Feb 17, 2012
Endo Pharmaceuticals to Present at J.P. Morgan Annual Global High Yield & Leveraged Finance Conference |
Feb 16, 2012
BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals |
Feb 13, 2012
Endo Pharmaceuticals to Present at Citi 2012 Global Health Care Conference |
Feb 03, 2012
Endo Pharmaceuticals to Announce Fourth Quarter and Full Year 2011 Financial Results on February 24, 2012 |
Jan 09, 2012
Endo Announces Potential Short-Term Supply Constraints of Certain Analgesic Medications as a Result of Temporary Shut Down of Novartis Facility |
Jan 06, 2012
Endo Pharmaceuticals and BioDelivery Sciences International Sign Licensing Agreement for BEMA Buprenorphine |
Dec 27, 2011
Endo Pharmaceuticals to Present at J.P. Morgan 30th Annual Healthcare Conference |
Dec 12, 2011
Endo Announces FDA Approval of a New Formulation of Opana® ER Designed To Be Crush-Resistant |
Nov 28, 2011
Qualitest Pharmaceuticals Receives FDA Approval for Myzilra(TM) Tablets (Levonorgestrel and Ethinyl Estradiol Tablets, USP), 0.05 mg/0.03 mg, 0.075 mg/0.04 mg, 0.125 mg/0.03 mg (28 - Day TriPhasic Regimen) |
Nov 23, 2011
Endo Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Leveraged Finance Conference |
Nov 22, 2011
Endo Pharmaceuticals to Present at the Piper Jaffray Annual Healthcare Conference |
Nov 14, 2011
Qualitest Pharmaceuticals Receives FDA Approval for Acetaminophen and Codeine Phosphate Oral Solution USP, 120mg/12mg per 5mL |
Nov 03, 2011
Endo Pharmaceuticals to Present at the 2011 Credit Suisse Annual Health Care Conference |
Nov 02, 2011
Endo Pharmaceuticals Receives FDA Approval for Felodipine Extended-Release Tablets USP, 2.5mg, 5mg and 10mg |
Oct 31, 2011
Endo Pharmaceuticals to Relocate From Chadds Ford, Pa., to New Facilities in Malvern |
Oct 27, 2011
Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance |
Oct 12, 2011
Endo Pharmaceuticals to Announce Third Quarter 2011 Financial Results on October 27, 2011 |
Sep 15, 2011
Qualitest Pharmaceuticals Issues a Nationwide Voluntary Recall of Oral Contraceptives |
Sep 13, 2011
Endo Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference |
Sep 07, 2011
Endo Pharmaceuticals to Present at the UBS Global Life Sciences Conference |
Aug 25, 2011
Endo Pharmaceuticals to Present at the Stifel Nicolaus Annual Healthcare Conference |
Aug 22, 2011
Endo Pharmaceuticals Announces Leadership Change at HealthTronics Subsidiary: Appoints Kelly Huang, Ph.D. New President |
Aug 17, 2011
Endo Pharmaceuticals Announces Termination of Collaboration with Grunenthal for the Development of Axomadol |
Aug 09, 2011
Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems |
Jul 26, 2011
Endo Pharmaceuticals to Announce Second Quarter 2011 Financial Results on August 9, 2011 |
Jun 30, 2011
Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain |
Jun 24, 2011
Qualitest Pharmaceuticals Issues Voluntary, Nationwide Retail Level Recall of Four Lots of Butalbital, Acetaminophen, and Caffeine Tablets, USP 50mg/325mg/40mg and Four Lots of Hydrocodone Bitartrate and Acetaminophen Tablets, USP 7.5MG/500MG |
Jun 24, 2011
Endo Pharmaceuticals Issues Voluntary, Nationwide Recall of Two Lots of Endocet® (Oxycodone/Acetaminophen, USP) Tablets, 10 Mg /325 Mg |
Jun 23, 2011
FDA Accepts Endo Pharmaceuticals' Complete Response for New Formulation of OPANA® ER |
Jun 20, 2011
Endo Pharmaceuticals Successfully Completes Acquisition of American Medical Systems for $2.9 Billion |
Jun 03, 2011
Endo Pharmaceuticals Holdings Inc. Announces Pricing of Private Offering of Senior Notes |
Jun 01, 2011
Endo Pharmaceuticals to Present at the Goldman Sachs Global Healthcare Conference |
May 31, 2011
Endo Pharmaceuticals to Present at the Jefferies Global Healthcare Conference |
May 26, 2011
Endo Pharmaceuticals Holdings Inc. Announces Proposed Private Offering of Senior Notes |
May 18, 2011
Qualitest Receives FDA Approval for Dexamethasone Elixir, USP, 0.5mg/ 5 mL and Orsythia(TM) Tablets (Levonorgestrel and Ethinyl Estradiol Tablets, USP, 0.1 mg/0.02 mg) |
May 17, 2011
Urocidin(TM) Phase III Clinical Trial Results Presented at AUA Conference in Washington, D.C. |
May 09, 2011
Endo Pharmaceuticals to Present at the Bank of America Merrill Lynch Healthcare Conference |
Apr 28, 2011
Endo Pharmaceuticals Reports Strong First Quarter 2011 Financial Results |
Apr 14, 2011
Endo Pharmaceuticals to Announce First Quarter 2011 Financial Results on April 28, 2011 |
Apr 11, 2011
Endo Announces Agreement to Acquire American Medical Systems for $2.9 Billion |
Mar 24, 2011
Qualitest Receives FDA Approval for Torsemide Tablets (Generic Demadex(R)) 5 mg, 10 mg, 20 mg, 100 mg, for the Treatment of Edema Associated with Congestive Heart Failure, Renal Disease, or Hepatic Disease |
Mar 09, 2011
Endo to Present at the Barclays Capital 2011 GlobalHealthcare Conference |
Mar 04, 2011
Qualitest Receives FDA Approval for Emoquette(TM) (.15 mg Desogestrel and .03 mg Ethinyl Estradiol), an Oral Contraceptive for Prevention of Pregnancy |
Mar 03, 2011
Endo Pharmaceuticals Launches FORTESTA(TM) (Testosterone) Gel for Topical Use Class III for Adult Men in the U.S. With Low Testosterone |
Mar 03, 2011
Endo Pharmaceuticals Appoints Dr. David Nash to Board of Directors |
Feb 28, 2011
Endo Pharmaceuticals Raises 2011 Financial Guidance and Reports Strong Fourth Quarter 2010 Financial Results |
Feb 17, 2011
Urocidin(TM) Phase III Clinical Trial Results to be Presented at EAU and AUA Conferences |
Feb 16, 2011
First Patient Enrolled in Second Phase III Clinical Trial of Urocidin(TM) |
Feb 11, 2011
Endo to Present at the 2011 RBC Capital Markets Healthcare Conference |
Feb 10, 2011
Endo To Present at the Citi 2011 Global Healthcare Conference |
Feb 09, 2011
Endo Pharmaceuticals to Announce Fourth Quarter and Full-Year 2010 Financial Results on February 28, 2011 |
Feb 07, 2011
Qualitest Pharmaceuticals Issues Voluntary, Nationwide Recall of Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10 mg / 500 mg, NDC 0603-3888-20, 60 Count, Lot Numbers T150G10B, T120J10E and T023M10A and Phenobarbital Tablets, USP 32.4 mg, NDC 0603-5166-32, 1000 Count, Lot Numbers T150G10B, T120J10E and T023M10A |
Jan 31, 2011
Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification |
Jan 28, 2011
Endo Pharmaceuticals and Orion Corporation Begin Novel R&D Collaboration |
Jan 07, 2011
Endo Pharmaceuticals Provides Regulatory Update on New Formulation of OPANA(R) ER Designed to be Crush-Resistant |
Jan 04, 2011
Endo to Present at the J.P. Morgan 29th Annual Healthcare Conference |
Dec 29, 2010
Endo Pharmaceuticals Receives FDA Approval for FORTESTA(TM) (Testosterone) Gel as a Class III Product for Topical Use for Men with Low Testosterone |
Dec 01, 2010
Endo Pharmaceuticals Successfully Completes Acquisition of Qualitest Pharmaceuticals for $1.2 Billion |
Nov 18, 2010
Endo Pharmaceuticals Holdings Inc. Announces Pricing of Private Offering of Senior Notes |
Nov 15, 2010
Endo Pharmaceuticals Holdings Inc. Announces Proposed Private Offering of Senior Notes |
Nov 09, 2010
Endo to Present at the Credit Suisse Healthcare Conference |
Nov 08, 2010
Endo Pharmaceuticals Announces That FDA Eliminates Need for Advisory Committee Meeting to Discuss New Formulation of Long-Acting Oxymorphone |
Nov 04, 2010
Penwest Pharmaceuticals Shareholders Approve Merger With Subsidiary of Endo Pharmaceuticals |
Nov 01, 2010
Endo Pharmaceuticals Reports Strong Third Quarter 2010 Financial Results; Reaffirms 2010 Financial Guidance and Provides Financial Guidance for 2011 |
Oct 20, 2010
Endo Pharmaceuticals to Announce Third Quarter 2010 Financial Results on November 1, 2010 |
Oct 05, 2010
Endo to Present at the Jefferies 2010 Global SpecPharma and European Healthcare Conference |
Sep 28, 2010
Endo Pharmaceuticals Announces Agreement to Acquire Qualitest Pharmaceuticals for $1.2 Billion |
Sep 22, 2010
Endo Pharmaceuticals Receives FDA Priority Review for New Formulation of Long-Acting Oxymorphone Designed to be Crush Resistant |
Sep 20, 2010
Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Penwest Pharmaceuticals |
Sep 15, 2010
Endo to Present at the Stifel Nicolaus Healthcare Conference 2010 |
Aug 09, 2010
Endo Pharmaceuticals Agrees to Acquire Penwest Pharmaceuticals and Submits NDA For New Formulation of Long-Acting Oxymorphone Designed to be Crush-Resistant |
Aug 06, 2010
Endo to Present at the Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference |
Jul 30, 2010
Endo Pharmaceuticals Reports Strong Second Quarter 2010 Financial Results |
Jul 20, 2010
Endo Pharmaceuticals to Announce Second Quarter 2010 Financial Results on July 30, 2010 |
Jul 19, 2010
Endo Pharmaceuticals Recognizes 10 Years as a Public Company by Ringing the NASDAQ Opening Bell |
Jul 15, 2010
Endo Pharmaceuticals Completes Acquisition of HealthTronics, Inc. |
Jul 12, 2010
Endo Pharmaceuticals Announces Expiration of Subsequent Offering Period of Tender Offer for HealthTronics, Inc. |
Jul 02, 2010
Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of HealthTronics, Inc. |
Jul 01, 2010
Endo Pharmaceuticals Completes Next Step in Regulatory Process for FORTESTA(TM) for Men With Low Testosterone |
Jun 08, 2010
Endo and Penwest Enter Into Agreement with Sandoz to Settle OPANA(R) ER Patent Litigation |
Jun 08, 2010
Endo and Penwest Enter Into Agreement with Impax Laboratories to Settle OPANA(R) ER Patent Litigation |
Jun 08, 2010
Endo to Present at Jefferies 2010 Global Life Sciences Conference |
May 05, 2010
Endo Pharmaceuticals To Acquire HealthTronics To Expand Its Delivery of Diversified Urology Treatment and Diagnostic Solutions |
May 04, 2010
Endo to Present at Bank of America Merrill Lynch Health Care Conference |
Apr 30, 2010
Endo Pharmaceuticals Reports Strong Revenue Growth and First Quarter 2010 Financial Results |
Apr 16, 2010
Endo Pharmaceuticals to Announce First Quarter 2010 Financial Results on April 30, 2010 |
Apr 13, 2010
Endo and Penwest Enter Into Agreement with Barr to Settle Patent Litigation Over Opana(R) ER |
Mar 17, 2010
Endo to Present at Barclays Capital Global Healthcare Conference |
Mar 12, 2010
Endo Pharmaceuticals Announces Appointment of New Chief Operating Officer |
Mar 05, 2010
Endo to Present at Cowen and Company 30th Annual Health Care Conference |
Feb 22, 2010
Endo Pharmaceuticals Reports Strong Fourth Quarter and Full-Year 2009 Financial Results: Provides 2010 Financial Guidance |
Feb 12, 2010
Endo Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Financial Results on February 22, 2010 |
Jan 19, 2010
Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification |
Dec 30, 2009
Endo to Present at J.P. Morgan 28th Annual Healthcare Conference |
Dec 03, 2009
Endo Pharmaceuticals Provides Regulatory Update on AVEED(TM) (Testosterone Undecanoate) Injection |
Nov 11, 2009
Endo Pharmaceuticals and LecTec Settle Patent Dispute |
Oct 29, 2009
Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full-Year Financial Guidance |
Oct 19, 2009
Endo Pharmaceuticals Gives Update on Regulatory Status of FORTESTA(TM) |
Oct 08, 2009
Endo Pharmaceuticals to Announce Third Quarter 2009 Financial Results on October 29, 2009 |
Sep 25, 2009
Endo Pharmaceuticals Announces Expiration of Cash Tender Offer for Ledgemont PhaRMA(SM) Secured 16% Notes |
Sep 03, 2009
Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer |
Sep 02, 2009
Endo Pharmaceuticals Gives Update on Regulatory Status of Testosterone Undecanoate for Men with Hypogonadism |
Aug 31, 2009
Endo Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2009 |
Aug 26, 2009
Endo Pharmaceuticals to Partner With ProStrakan to Commercialize FORTESTA(TM) in the U.S. |
Aug 26, 2009
Endo Pharmaceuticals Announces Cash Tender Offer for Any and All Outstanding Ledgemont PhaRMA(SM) Secured 16% Notes |
Aug 12, 2009
Endo Pharmaceuticals Announces Resignation of Chief Operating Officer |
Jul 30, 2009
Endo Pharmaceuticals Reports Strong Second Quarter 2009 Financial Results |
Jul 10, 2009
Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM) |
Jul 01, 2009
Endo Pharmaceuticals to Announce Second Quarter 2009 Financial Results on July 30, 2009 |
Jun 10, 2009
Men with Low Testosterone See Multiple Doctors Before Being Diagnosed; Many Dissatisfied with Current Treatment Options |
Jun 09, 2009
Penwest and Endo Grant Valeant Pharmaceuticals Exclusive License to Market Opana(r) ER in Canada, Australia and New Zealand |
Jun 05, 2009
Endo Pharmaceuticals to Present at Goldman Sachs 30th Annual Healthcare Conference |
May 29, 2009
Endo Announces Compensation for New CFO Alan Levin |
May 07, 2009
Endo Pharmaceuticals Appoints Alan G. Levin as Chief Financial Officer |
May 06, 2009
Endo to Present at Bank of America and Merrill Lynch 2009 Health Care Conference |
Apr 29, 2009
Endo Pharmaceuticals Reports First Quarter 2009 Financial Results |
Apr 28, 2009
Testosterone Undecanoate Achieves and Maintains Normal Testosterone Levels in Hypogonadal Men With Five Injections Per Year, New Data Show |
Apr 08, 2009
Endo Pharmaceuticals to Announce First Quarter 2009 Financial Results on April 29, 2009 |
Mar 30, 2009
Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors |
Mar 25, 2009
Exercise Physiologist and Celebrity Trainer Bob Greene Leads National Campaign to Showcase Osteoarthritis Pain Management Techniques and New Treatment Approaches |
Mar 23, 2009
Endo Pharmaceuticals Completes Acquisition of Indevus Pharmaceuticals |
Mar 19, 2009
Endo Pharmaceuticals Announces Successful Completion of Tender Offer for Indevus Pharmaceuticals |
Mar 16, 2009
Endo Pharmaceuticals Extends Subsequent Offering Period for Indevus Shares Until 5:00 pm EDT on Wednesday, March 18, 2009 |
Mar 12, 2009
FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R) |
Mar 02, 2009
Endo Pharmaceuticals Announces Extension of its Tender Offer for Shares of Indevus Pharmaceuticals |
Feb 27, 2009
Endo Licenses Novel Pain Therapy from Grunenthal |
Feb 27, 2009
Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results |
Feb 26, 2009
Endo Pharmaceuticals Appoints William Montague to Board of Directors |
Feb 23, 2009
Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period |
Feb 20, 2009
Endo and Penwest Announce Settlement of Opana(R) ER Litigation |
Feb 10, 2009
Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments |
Feb 09, 2009
Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study |
Feb 04, 2009
Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results |
Jan 29, 2009
Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude
Research Collaboration |
Jan 28, 2009
Endo Pharmaceuticals to Announce Fourth Quarter and 2008 Full-Year Financial Results on February 27, 2009 |
Jan 09, 2009
Endo Pharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference |
Jan 05, 2009
Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals |
Jan 05, 2009
Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals |
Dec 01, 2008
Endo Announces Resignation of Board Member |
Nov 25, 2008
Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results |
Nov 18, 2008
Indevus Pharmaceuticals to Announce Fiscal 2008 Financial Results on Tuesday, November 25, 2008 |
Nov 17, 2008
Endo Pharmaceuticals Announces Acceptance of UBS AG Settlement Offer Relating to Auction Rate Securities |
Oct 30, 2008
Endo Pharmaceuticals Reports Strong Third Quarter Financial Results |
Oct 28, 2008
Indevus Pharmaceuticals to Present at Upcoming Investor Conferences |
Oct 13, 2008
Endo Pharmaceuticals to Hold Conference Call and Webcast on Third Quarter 2008 Financial Results |
Sep 30, 2008
Indevus Announces Initiation of Phase III Clinical Trial of Octreotide Implant for Acromegaly |
Sep 26, 2008
Indevus and FDA Agree on Path Forward for NEBIDO(R) |
Sep 26, 2008
Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering |
Sep 16, 2008
Indevus Pharmaceuticals Scheduled to Present at 2008 UBS Global Life Sciences Conference |
Sep 02, 2008
Endo Pharmaceuticals Announces Resignation of Chief Financial Officer |
Aug 26, 2008
Indevus Announces Private Placement of $105 Million of Non-Recourse Notes |
Aug 22, 2008
Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000 |
Aug 13, 2008
Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM) |
Aug 11, 2008
Endo Pharmaceuticals Appoints Dr. Sandeep Gupta, Senior Vice President, Discovery and Early Development |
Aug 05, 2008
Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results |
Jul 31, 2008
Endo Pharmaceuticals Reports Strong Second Quarter Financial Results |
Jul 29, 2008
Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008 |
Jul 22, 2008
Endo Pharmaceuticals to Hold Conference Call and Webcast on Second Quarter 2008 Financial Results |
Jun 30, 2008
Indevus Receives Approvable Letter from FDA for NEBIDO(R) |
Jun 12, 2008
Indevus Announces Management Changes |
Jun 04, 2008
Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status |
May 22, 2008
Endo Pharmaceuticals Appoints Blaine T. Davis as Vice President, Investor Relations and Corporate Communications |
May 22, 2008
Indevus Pharmaceuticals Licenses Canadian Rights for SANCTURA XR(TM) to Allergan, Inc. |
May 20, 2008
Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association |
May 15, 2008
Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences |
May 05, 2008
Two Year Study Confirms SUPPRELIN(R) LA Implant Maintains Profound Suppression of Hormones in Children With Premature Onset Puberty |
Apr 30, 2008
Indevus Pharmaceuticals Announces Second Quarter Fiscal 2008 Financial Results |
Apr 30, 2008
Endo Pharmaceuticals Reports First Quarter Financial Results |
Apr 30, 2008
Endo Pharmaceuticals and the D.E. Shaw Group Agree to Settlement |
Apr 24, 2008
Endo Pharmaceuticals to Hold Conference Call on First Quarter 2008 Financial Results |
Apr 23, 2008
Indevus to Announce Second Quarter Fiscal 2008 Financial Results on Wednesday, April 30, 2008 |
Apr 11, 2008
Endo Announces Executive Appointment |
Apr 10, 2008
Endo Pharmaceuticals Holdings Inc. Prices Private Offering of Convertible Senior Subordinated Notes |
Apr 09, 2008
Endo Pharmaceuticals Holdings Inc. Announces Stock Repurchase Program and Proposed Private Offering of Convertible Senior Subordinated Notes |
Apr 07, 2008
Endo Pharmaceuticals Provides Updates on FROVA(R) and CHRONOGESIC(R) Clinical Development Programs |
Apr 03, 2008
Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation |
Mar 28, 2008
Endo and Penwest File Lawsuit Against Actavis Relating to Opana(R) ER |
Mar 20, 2008
125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative |
Mar 12, 2008
Endo Pharmaceuticals Names David P. Holveck President and Chief Executive Officer |
Mar 11, 2008
Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference |
Mar 04, 2008
Endo Licenses U.S. Rights for Voltaren(R) Gel -- the First FDA-Approved Topical Treatment for Relief of Osteoarthritis Pain |
Mar 03, 2008
Endo Pharmaceuticals to Launch Three New Dosage Strengths of OPANA(R) ER |
Mar 03, 2008
Indevus Pharmaceuticals Announces Retirement Plans For Its CEO and Chairman |
Feb 22, 2008
Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results for 2007 |
Feb 18, 2008
Endo Pharmaceuticals to Hold Conference Call on Fourth Quarter and Full-Year 2007 Financial Results |
Feb 15, 2008
Indevus Pharmaceuticals Provides Update on PRO 2000 Program |
Feb 15, 2008
Endo and Penwest Receive Paragraph IV Certification Notice From Actavis for OPANA(R) ER |
Feb 07, 2008
Indevus Pharmaceuticals Announces First Quarter Fiscal 2008 Financial Results |
Jan 31, 2008
Indevus To Announce First Quarter Fiscal 2008 Financial Results On Thursday, February 7, 2008 |
Jan 28, 2008
Peter A. Lankau Resigns as President and CEO of Endo Pharmaceuticals |
Jan 25, 2008
Endo and Penwest File Lawsuit Against Impax Laboratories Relating to OPANA(R) ER |
Jan 22, 2008
Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R) |
Jan 07, 2008
Endo Pharmaceuticals Provides Financial Guidance for 2008 |
Dec 27, 2007
Endo Pharmaceuticals to Develop and Commercialize Alexza's AZ-003 Staccato(R) Inhaled Fentanyl Product |
Dec 20, 2007
Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R) |
Dec 19, 2007
Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM) |
Dec 17, 2007
Endo Announces Positive Results From Interim Analysis of RAPINYL(TM) Phase III Clinical Trial |
Dec 17, 2007
Endo and Penwest Receive New Paragraph IV Certification Notice From IMPAX for OPANA(R) ER |
Dec 05, 2007
Indevus Pharmaceuticals To Present at RBC Capital Markets Conference |
Nov 29, 2007
Indevus Pharmaceuticals Announces Fiscal 2007 |
Nov 28, 2007
Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial |
Nov 26, 2007
Indevus Pharmaceuticals to Announce Fiscal 2007 Financial Results on Thursday, November 29, 2007 |
Nov 15, 2007
Endo and Penwest File Lawsuit Against IMPAX Laboratories Relating to OPANA(R) ER |
Nov 01, 2007
FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus |
Nov 01, 2007
Endo Pharmaceuticals Reports Third Quarter 2007 Financial Results |
Oct 30, 2007
Indevus Pharmaceuticals to Present at Upcoming Investor Conferences |
Oct 23, 2007
Endo Pharmaceuticals to Hold Conference Call on Third Quarter 2007 Financial Results |
Oct 22, 2007
Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors |
Oct 03, 2007
Endo and Penwest Receive Paragraph IV Certification Notice for OPANA(R) ER |
Sep 30, 2007
Endo Pharmaceuticals and Vernalis Receive Action Letter From FDA on FROVA(R) Supplemental New Drug Application |
Sep 27, 2007
Indevus Pharmaceuticals to Present at Think Equity Partners ThinkClinic Conference |
Sep 26, 2007
ALKERMES AND INDEVUS ANNOUNCE POSITIVE RESULTS FROM PHASE 2a CLINICAL STUDY OF ALKS 27 FOR THE TREATMENT OF COPD |
Sep 19, 2007
Indevus Announces Allergan as New Partner for SANCTURA Brand |
Sep 17, 2007
Indevus Pharmaceuticals to Present at Upcoming Investor Conferences |
Sep 10, 2007
FDA Informs Endo and Vernalis That New Target Action Date on Frova(R) sNDA Is Sept. 30, 2007 |
Sep 06, 2007
Endo Pharmaceuticals Appoints Nancy Wysenski Chief Operating Officer |
Aug 28, 2007
Indevus Announces Submission of New Drug Application |
Aug 17, 2007
Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy |
Aug 16, 2007
Endo and Vernalis Provide Update on Frova(R) |
Aug 13, 2007
Indevus Announces Receipt of $49.9 Million Milestone Payment from Esprit Pharma |
Aug 07, 2007
Indevus Pharmaceuticals Announces Third Quarter Fiscal 2007 Financial Results |
Aug 07, 2007
Indevus Pharmaceuticals, Inc. Announces Final Results of Exchange Offer for its 6.25% Convertible Senior Notes Due July 2008 |
Aug 06, 2007
Indevus Announces FDA Approval of SANCTURA(R) XR |
Aug 01, 2007
Endo Pharmaceuticals Reports 2007 Second Quarter Financial Results |
Jul 31, 2007
Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2007 Financial Results on August 7, 2007 |
Jul 25, 2007
Endo Pharmaceuticals to Hold Conference Call on Second Quarter 2007 Financial Results |
Jul 11, 2007
Endo Provides Update on Clinical Development Program for Ketoprofen Patch |
Jul 09, 2007
Indevus Pharmaceuticals, Inc. Commences Exchange Offer for Its 6.25% Convertible Senior Notes due July 2008 |
Jun 29, 2007
Indevus Appoints Industry Veteran Kurt Lewis as Senior Vice President Sales & Marketing |
Jun 25, 2007
Indevus Announces Launch of SUPPRELIN(R) LA for Central Precocious Puberty |
Jun 13, 2007
Endo Pharmaceuticals Contributes More Than 200,000 Synera® Patches To Americares |
Jun 12, 2007
Indevus Announces Presentation of Pagoclone Data at 47th Annual New Clinical Drug Evaluation Unit Meeting |
Jun 09, 2007
FROVA (R) Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine |
Jun 07, 2007
Indevus Reports Positive Data From Phase III NEBIDO(R) Trial |
May 31, 2007
Indevus Announces Authorization for Approval of VANTAS(R) in Selected European Countries |
May 23, 2007
Indevus to Present at the 2007 FBR Growth Conference |
May 15, 2007
Indevus to Present at the Sixth Annual JMP Securities Research Conference |
May 11, 2007
Indevus to Present at the Citigroup Healthcare Conference |
May 09, 2007
Indevus Pharmaceuticals Announces Second Quarter Fiscal 2007 Financial Results |
May 07, 2007
Indevus Pharmaceuticals Scheduled to Present at Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference |
May 03, 2007
Indevus Announces FDA Approval of SUPPRELIN(R)-LA |
May 02, 2007
Indevus Pharmaceuticals to Announce Second Quarter Fiscal 2007 Financial Results on May 9, 2007 |
May 01, 2007
Indevus To Present at UBS Global Generic and Specialty Pharmaceuticals Conference |
Apr 27, 2007
Endo Pharmaceuticals Reports First Quarter 2007 Financial Results |
Apr 25, 2007
Alkermes and Indevus Announce Initiiation of Phase 2a Clinical Study Of ALKS 27 For the Treatment of COPD |
Apr 20, 2007
Endo Pharmaceuticals to Hold Conference Call on First Quarter 2007 Financial Results |
Apr 19, 2007
Indevus Announces Submission of Supplemental NDA to Reintroduce VALSTAR(R) to Treat Bladder Cancer |
Apr 17, 2007
Indevus and Valera Announce Completion of Merger |
Apr 12, 2007
Indevus and Valera Announce Merager Exchange Ratio |
Apr 10, 2007
Endo Comments on Notices Received From Anesiva |
Apr 09, 2007
Endo Pharmaceuticals Announces Retirement of Chairman Carol Ammon |
Apr 05, 2007
Indevus to Present at CIBC Annual Biotechnology & Specialty Pharmaceuticals Conference |
Apr 04, 2007
Institutional Shareholder Services and Glass Lewis Support Indevus' Acquisition of Valera Pharmaceuticals |
Mar 26, 2007
Indevus Reports That Interim Review of NEBIDO(R) Phase III Data Indicates Trial Is Likely to Meet Primary Endpoints |
Mar 16, 2007
Endo and Vernalis plc Announce Three-Month Extension of PDUFA Date for Frova(R) sNDA |
Feb 22, 2007
Endo Pharmaceuticals Reports Fourth Quarter and Full-Year 2006 Financial Results |
Feb 15, 2007
Endo Pharmaceuticals to Hold Conference Call on Fourth Quarter and Full-Year 2006 Financial Results |
Feb 07, 2007
Indevus Pharmaceuticals Announces First Quarter Fiscal 2007 Financial Results |
Feb 01, 2007
Indevus Pharmaceuticals To Announce First Quarter Fiscal 2007 Financial Results on February 7, 2007 |
Jan 17, 2007
Endo Pharmaceuticals Receives Subpoena From U.S. Department of Health and Human Services |
Jan 08, 2007
Endo Pharmaceuticals Provides Financial Guidance for 2007 |
Jan 08, 2007
Endo and Penwest Agree to Amend Opana(R) ER Contract |
Jan 05, 2007
Endo Pharmaceuticals to Hold 2007 Financial Guidance Conference Call |
Jan 04, 2007
Alkermes and Indevus Announce Joint Collaboration to Develop Inhaled Formulation of Trospium Chloride for the Treatment of COPD |
Dec 20, 2006
Endo Pharmaceuticals' CEO to Present at JP Morgan Healthcare Conference |
Dec 19, 2006
Endo Pharmaceuticals Submits Citizen Petition to FDA Regarding Lidoderm(R) |
Dec 06, 2006
Endo Pharmaceuticals Appoints Charles Rowland as Chief Financial Officer |
Oct 19, 2006
Endo Pharmaceuticals Reports Third Quarter 2006 Financial Results |
Oct 17, 2006
Endo Pharmaceuticals Comments on Lidoderm(R) |
Oct 12, 2006
Endo Pharmaceuticals Acquires RxKinetix, Inc. |
Oct 10, 2006
Endo Pharmaceuticals to Hold Conference Call on Third Quarter 2006 Financial Results |
Oct 02, 2006
Endo Signs Inventory Management Agreement With Major Wholesaler |
Aug 28, 2006
Endo Pharmaceuticals Announces Settlement of OxyContin(R) Patent Case |
Aug 17, 2006
Endo Comments on Recent Announcement by Penwest Pharmaceuticals, Its Development Partner on Opana(R) ER |
Aug 09, 2006
Endo Pharmaceuticals Appoints New Independent Outside Director |
Jul 24, 2006
Endo Announces Commercial Availability of Opana(R) ER (oxymorphone HCl) Extended-Release and Opana(R) (oxymorphone HCl) Immediate-Release Tablets CII |
Jul 20, 2006
Endo Pharmaceuticals Reports 2006 Second Quarter Financial Results |
Jul 19, 2006
Endo Pharmaceuticals and Vernalis plc Announce the Filing of the Supplemental NDA for Frova(R) for Short-Term Prevention of Menstrual Migraine |
Jul 13, 2006
Endo Pharmaceuticals to Hold Conference Call on Second Quarter 2006 Financial Results |
Jun 23, 2006
Endo Receives FDA Approval for Opana(R) ER (oxymorphone HCl) Extended-Release and Opana(R) (oxymorphone HCl) Immediate Release Tablets CII |
Jun 19, 2006
Endo Launches Synera(TM), a New Topical Anesthetic Patch |
May 08, 2006
Frova(R) Meets Primary Endpoint in Second Phase III Study for Prevention of Menstrual Migraine |
May 04, 2006
Oxymorphone Studies Presented at American Pain Society Annual Meeting |
Apr 20, 2006
Endo Pharmaceuticals Reports First Quarter 2006 Financial Results |
Apr 19, 2006
Endo Pharmaceuticals Announces Upcoming Retirement of CFO Jeff Black |
Apr 12, 2006
Endo Pharmaceuticals to Hold Conference Call on First Quarter 2006 Financial Results |
Mar 21, 2006
Endo Announces Pricing of Common Stock Offering |
Mar 08, 2006
Endo Announces Changes in Corporate Board |
Feb 15, 2006
Endo Pharmaceuticals Reports Fourth Quarter and Full-Year 2005 Financial Results |
Feb 09, 2006
Endo Pharmaceuticals to Hold Conference Call on Fourth Quarter and Full-Year 2005 Financial Results |
Feb 06, 2006
Endo Pharmaceuticals to Continue to Market Its Bioequivalent Version of OxyContin |
Feb 01, 2006
Endo Pharmaceuticals Announces Federal Circuit Court of Appeals Remands OxyContin Patent Case |
Jan 19, 2006
Endo Announces Pricing of Common Stock Offering |
Jan 11, 2006
Endo Pharmaceuticals Honors Those 'Making A Difference' in Chronic Pain |
Jan 09, 2006
Endo Pharmaceuticals to Hold 2006 Financial Guidance Conference Call |
Jan 09, 2006
Endo Announces License Agreement With ZARS for Synera(TM), an FDA-Approved Topical Local Anesthetic Patch |
Jan 09, 2006
Endo Pharmaceuticals Issues Conference Call Advisory |
Jan 09, 2006
Endo Pharmaceuticals Provides Financial Guidance for 2006 |
Jan 06, 2006
Endo Pharmaceuticals Appoints New Outside Director to Board |
Dec 22, 2005
Endo Files Responses to FDA's Approvable Letters on NDAs for Oxymorphone ER and IR Tablets |
Nov 16, 2005
Data Reported From First Head-To-Head Study Evaluating Lidoderm(R) and Celebrex(R) in Treating Chronic Low Back Pain |
Oct 27, 2005
Results Reported in Open-Label Pilot Study of Lidoderm(R) in Treating Pain Associated With Carpal Tunnel Syndrome |
Oct 20, 2005
Endo Pharmaceuticals Reports Third Quarter 2005 Financial Results |
Oct 12, 2005
Endo Pharmaceuticals Completes Secondary Offering |
Oct 06, 2005
Endo Announces Pricing of Secondary Offering of Common Stock |
Oct 03, 2005
Endo Announces Positive Results From Second Study of Extended-Release Oxymorphone |
Sep 28, 2005
Endo Pharmaceuticals Provides Update On Its Developmental Transdermal Fentanyl Patch |
Sep 26, 2005
Endo Announces Secondary Offering of Common Stock |
Sep 02, 2005
Endo Files Shelf Registration Statement for Secondary Sale of 19 Million Currently Issued and Outstanding Shares of Common Stock |
Aug 22, 2005
Endo Announces Positive Results From Its Extended-Release Oxymorphone Study |
Jul 22, 2005
Endo Pharmaceuticals To Submit Response Brief To The Federal Circuit Court of Appeals |
Jul 21, 2005
Endo Pharmaceuticals Reports 2005 Second Quarter Financial Results |
Jul 13, 2005
Endo Pharmaceuticals to Hold Conference Call on Second Quarter 2005 Financial Results |
Jun 07, 2005
Endo Pharmaceuticals Announces Favorable Appellate Court Ruling On Generic Oxycodone Extended-Release Product |
Apr 21, 2005
Endo Pharmaceuticals Reports First Quarter Financial Results |
Apr 19, 2005
Endo Pharmaceuticals to Hold Conference Call on First Quarter 2005 Financial Results |
Apr 12, 2005
Serena Williams Launches 'RALLY for Menstrual Migraine' Campaign With Endo Pharmaceuticals |
Mar 31, 2005
First Head-To-Head Study to Compare Lidoderm Patch and Celebrex in Treating Pain Associated With Osteoarthritis of the Knee |
Mar 14, 2005
Endo Pharmaceuticals to Develop and Commercialize Durect's Seven-Day Transdermal Pain Patch |
Mar 14, 2005
Endo Licenses Topical Ketoprofen Patch |
Mar 09, 2005
Endo Announces Appointment of Peter A. Lankau to Position of Chief Executive Officer |
Feb 10, 2005
Endo Pharmaceuticals Reports Full-Year and Fourth Quarter 2004 Financial Results |
Feb 03, 2005
Endo Pharmaceuticals to Hold Conference Call on Fourth Quarter and Full-Year 2004 Financial Results |
Dec 22, 2004
Endo Pharmaceuticals Provides Financial Guidance For 2005 |
Dec 22, 2004
Endo Announces Executive Appointments |
Dec 20, 2004
Endo Pharmaceuticals to Hold Financial Guidance Conference Call |
Dec 06, 2004
Two Days of Post-Surgical Pain Relief Now Possible With Just One Shot |
Nov 23, 2004
Endo Announces Pricing of Secondary Offering of Common Stock |
Nov 22, 2004
Endo Announces Final FDA Approval of the Protocol for Its Oxymorphone Extended-Release Tablets |
Nov 12, 2004
Eastern Technology Council Names Endo's Carol A. Ammon CEO of the Year |
Oct 26, 2004
DepoDur(TM) Found to Be Innovative Option for Postoperative Pain Relief |
Oct 14, 2004
Endo Pharmaceuticals Reports Third Quarter 2004 Financial Results |
Oct 06, 2004
Endo Pharmaceuticals to Hold Conference Call on Third Quarter 2004 Financial Results |
Sep 21, 2004
Endo Announces Date for Appellate Court Hearing |
Sep 20, 2004
Endo Provides Update on Status of Oxymorphone Program |
Aug 18, 2004
Endo Licenses the Rights to Develop and Market Proprietary Sublingual Fentanyl Product From Orexo |
Aug 17, 2004
Endo Announces Closing of License Agreement on Frova(R) |
Aug 04, 2004
Endo Announces Pricing of Secondary Offering of Common Stock |
Jul 14, 2004
Endo Pharmaceuticals Reports Second Quarter Financial Results |
Jul 14, 2004
Endo Licenses Rights from Vernalis to Market Acute Migraine Treatment Frova(TM) |
Jul 09, 2004
Endo Pharmaceuticals to Hold Conference Call on Second Quarter 2004 Financial Results |
Jul 07, 2004
Endo Announces Agreement With FDA for New Trial Design of Oxymorphone Extended-Release Product |
May 19, 2004
SkyePharma and Endo Announce FDA Approval of Depodur(TM) (previously referred to as DepoMorphine(TM)) |
May 17, 2004
Endo Pharmaceuticals Plans to Launch Its Generic Oxycodone Extended-Release Tablets After Appellate Court Decision |
May 13, 2004
New Study Reveals Analgesic Patch Lidoderm(R) May Reduce Pain Of Osteoarthritis |
May 07, 2004
New Data Reveal the Analgesic Patch Lidoderm(R) May Improve Pain Intensity and Common Pain Qualities Associated with Low-Back Pain and Osteoarthritis |
May 07, 2004
Data Demonstrate Innovative Single-Shot Epidural Injection Provides 48-Hour Pain Relief Following Surgery |
May 06, 2004
Endo Announces The Results Of The Meeting With The FDA On Oxymorphone Extended-Release |
Apr 30, 2004
Endo Files Shelf Registration Statement for Secondary Sale of 30 Million Shares of Common Stock |
Apr 21, 2004
Endo Pharmaceuticals Reports First Quarter Financial Results |
Apr 12, 2004
Endo Pharmaceuticals to Hold Conference Call on First Quarter 2004 Financial Results |
Mar 31, 2004
ENDO Announces Outcome of Recent FDA Meeting on oxymorphone NDAs |
Mar 24, 2004
Endo Pharmaceuticals Receives Final FDA Approval For Oxycodone Extended-Release Tablets |
Mar 01, 2004
Endo Announces Agreement With MakScientific for Development of New Drugs for Pain |
Feb 26, 2004
Noven and Endo Announce Licensing Agreement for Fentanyl Patch |
Feb 05, 2004
Endo Pharmaceuticals Reports 2003 Full-Year and Fourth Quarter Results |
Jan 23, 2004
Endo Pharmaceuticals to Hold Conference Call on Fourth Quarter and Full-Year 2003 Financial Results |
Jan 05, 2004
Endo Pharmaceuticals Announces Favorable Court Ruling On Generic Oxycodone Extended-Release Product |
Dec 22, 2003
Endo Announces Executive Appointments |
Dec 18, 2003
Endo Licenses EpiCept Patents for Back Pain and Commercial Rights to LidoPAIN(R) BP Product |
Dec 18, 2003
Endo Pharmaceuticals Updates 2003 Guidance And Provides Financial Guidance for 2004 |
Dec 17, 2003
Endo Pharmaceuticals to Hold Financial Guidance Conference Call |
Nov 18, 2003
First-of-a-kind Pain Management Guidelines Published in Archives of Neurology |
Nov 18, 2003
Endo Pharmaceuticals Named Company of the Year |
Oct 24, 2003
Endo Pharmaceuticals Announces Results For Investigational Oral Mucositis Rinse |
Oct 23, 2003
Endo Pharmaceuticals Reports 2003 Third Quarter Results |
Oct 20, 2003
Endo Receives Approvable Letters From FDA for Oxymorphone Extended-Release and Immediate-Release Formulations |
Oct 09, 2003
Endo Pharmaceuticals to Hold Conference Call on Third Quarter 2003 Financial Results |
Sep 22, 2003
Endo Announces that FDA has Accepted DepoMorphine(TM) NDA for Filing |
Sep 15, 2003
Endo Pharmaceuticals Announces Plans to Convert Pharma Sales Force |
Jul 24, 2003
Endo Pharmaceuticals Reports 2003 Second Quarter Results |
Jul 21, 2003
Endo Pharmaceuticals Announces NDA Submitted on DepoMorphine(TM) By Partner SkyePharma |
Jul 15, 2003
Endo Pharmaceuticals To Hold Conference Call on Second Quarter 2003 Financial Results |
Jul 11, 2003
Endo Pharmaceuticals Announces Closing of Over-Allotment Shares |
Jul 09, 2003
Endo Pharmaceuticals Executives Receive Ernst & Young Entrepreneur Of The Year(R) Award |
Jul 01, 2003
Endo Announces Pricing of Secondary Offering of Common Stock |
May 16, 2003
Endo Files Registration Statement for Secondary Offering of Common Stock |
Apr 24, 2003
Endo Pharmaceuticals Reports 2003 First Quarter Results |
Apr 16, 2003
Endo Pharmaceuticals to Hold Conference Call For First Quarter 2003 Financial Results |
Apr 09, 2003
Endo Pharmaceuticals Names Peter A. Lankau President And Chief Operating Officer |
Mar 25, 2003
Endo Pharmaceuticals Increases Financial Guidance for 2003 |
Mar 20, 2003
Lidoderm(R) Pilot Phase IV Studies Presented at American Pain Society Meeting |
Mar 20, 2003
Clinical Trial of New Opioid Product Shows Pain Reduction in Chronic Low Back Pain |
Feb 19, 2003
FDA Accepts New Drug Application for Oxymorphone Extended Release And Immediate Release Formulations |
Feb 13, 2003
Endo Pharmaceuticals Reports 2002 Fourth Quarter and Full-Year Results |
Feb 07, 2003
Endo Pharmaceuticals to Hold Conference Call On Fourth Quarter Earnings |
Jan 15, 2003
Endo Pharmaceuticals Announces Appointment of New Outside Director to Board |
Jan 08, 2003
Endo Pharmaceuticals Announces the Exercisability of Pre-Merger Endo Warrants |
Jan 03, 2003
Endo Pharmaceuticals Licenses Rights from SkyePharma For Two Critical Care Products |
Dec 30, 2002
Endo Pharmaceuticals Provides Financial Guidance for 2003 |
Dec 20, 2002
Endo Pharmaceuticals Appoints New Outside Director to Board |
Dec 20, 2002
Endo Pharmaceuticals to Hold Financial Guidance Conference Call |
Dec 20, 2002
Endo Pharmaceuticals Submits New Drug Application For Immediate Release Oxymorphone |
Dec 19, 2002
Endo Pharmaceuticals Announces Results From Its Third MorphiDex(R) Phase III Clinical Trial |
Dec 19, 2002
Endo Pharmaceuticals Submits New Drug Application for Extended Release Oxymorphone |
Nov 11, 2002
Endo Pharmaceuticals and DURECT Corporation Agree To Collaborate on Treatment in Pain Management |
Oct 28, 2002
Endo Pharmaceuticals Announces Results From MorphiDex(R) Phase III Clinical Trial |
Oct 24, 2002
Endo Pharmaceuticals Reports Third Quarter Results - Net Sales Up 67% - - Consolidated EBITDA Nearly Double the Year-Ago Quarter - - Company Increases Guidance for 2002 - |
Oct 23, 2002
Endo Pharmaceuticals to Hold Conference Call on Third Quarter Earnings |
Aug 26, 2002
Endo Pharmaceuticals Amends Manufacturing Agreement With Bristol-Myers Squibb |
Aug 21, 2002
Data from Studies Investigating Extended-Release Oxymorphone Presented Today at 10th World Congress on Pain |
Aug 01, 2002
Endo Pharmaceuticals Announces Tentative FDA Approval Of Its Oxycodone Extended-Release Product |
Jul 29, 2002
Correction: /Correction -- Endo Pharmaceuticals Holdings Inc. |
Jul 29, 2002
Endo Pharmaceuticals Acquires BML Pharmaceuticals, Inc. - Acquisition Includes Product in Late-Stage Clinical Development |
Jul 25, 2002
Endo Pharmaceuticals Reports Strong Second Quarter Results |
Jul 18, 2002
Endo Pharmaceuticals to Hold Conference Call on Second Quarter Earnings |
Jun 24, 2002
Endo Pharmaceuticals Announces Results from MorphiDex(R) Phase III Clinical Trial |
May 30, 2002
Endo Pharmaceuticals Announces Plans to Convert Specialty Sales Force |
Apr 25, 2002
Endo Pharmaceuticals Achieves Strong First Quarter 2002 Financial Results |
Feb 20, 2002
Endo Pharmaceuticals Achieves Strong 2001 Financial Results |
Jan 28, 2002
Endo Pharmaceuticals Holdings Inc. Announces Results of Tender Offer |
Jan 18, 2002
Endo Pharmaceuticals Holdings Inc. Extends Warrant Tender Offer |
Jan 17, 2002
Endo Pharmaceuticals (Nasdaq: ENDP; ENDW) Conference Call |
Jan 16, 2002
Endo Pharmaceuticals Holdings Inc. Extends Warrant Tender Offer, Provides Morphidex(R) Update |
Jan 14, 2002
Endo Pharmaceuticals Holdings Inc. Announces Extension of Offer To Purchase for Cash Up to 13,500,000 Class A Transferable Warrants and Any and All Class B Non-Transferable Warrants at $0.75 Per ... |
Jan 14, 2002
Endo Pharmaceuticals Holdings Inc. Announces Extension of Offer To Purchase for Cash Up to 13,500,000 Class A Transferable Warrants and Any and All Class B Non-Transferable Warrants at $0.75 Per Warrant |
Dec 14, 2001
Endo Pharmaceuticals Holdings Inc. Permits Board Members and Executive Officers to Enter Into Rule 10b5-1 Trading Plans |
Dec 05, 2001
Endo Pharmaceuticals Holdings Inc. Announces Tender Offer for up to 13, 500,000 of its Class A Transferable Warrants and Any and All of its Class B Non-Transferable Warrants at $0.75 net per Warrant |
Nov 26, 2001
Endo Receives FDA Approval for New Percocet(R) Strengths; Reduced Acetaminophen Should Ease Concern About Daily Acetaminophen Limits |
Nov 19, 2001
Endo Pharmaceuticals Announces Closing of Over-Allotment Shares |
Nov 16, 2001
Endo Pharmaceuticals Challenges SmithKline Beecham's Paxil(R) (Paroxetine Hydrochloride, 40 mg) Patents |
Nov 13, 2001
Endo Pharmaceuticals Achieves Strong Third Quarter and Year-to-Date 2001 Financial Results |
Oct 18, 2001
Endo Pharmaceuticals Holdings Inc. Announces Pricing of Public Offering |
Sep 07, 2001
Endo Pharmaceuticals Holdings Inc. Files for Public Offering of Common Stock |
Sep 04, 2001
Endo Pharmaceuticals Challenges The Purdue Frederick Company's OxyContin(R) (Oxycodone Hydrochloride Extended-Release Tablets, 80 mg) Patents |
Aug 13, 2001
Endo Pharmaceuticals Achieves Strong Second Quarter and Year-to-Date 2001 Financial Results - Net Sales Increase 62% and Gross Profit Rises by 82% for the Period - |
May 14, 2001
Endo Pharmaceuticals Reports First Quarter 2001 Financial Results |
May 14, 2001
Lidocaine Patch Shown in Large Trial to Relieve Post-Herpetic Neuralgia; Most Patients with Pain After Shingles Had Pain Relief Within a Week |
Mar 22, 2001
Endo Pharmaceuticals Challenges the Purdue Frederick Company's Oxycontin(R) (Oxycodone Hydrochloride Extended-Release Tablets, 10 and 20 mg) Patents |
Mar 14, 2001
Endo Pharmaceuticals Reports Year End 2000 Financial Results |
Nov 13, 2000
Endo Pharmaceuticals Reports Third Quarter and Nine-Month 2000 Financial Results |
Oct 25, 2000
Endo Pharmaceuticals Challenges The Purdue Frederick Company's Oxycontin(R) (Oxycodone Hydrochloride Extended-Release Tablets, 40 mg) Patents |
Sep 27, 2000
Endo Pharmaceuticals Announces Appointment of New Director and Hiring of Two New Executive Officers and Two New Executives |
Sep 26, 2000
Endo Pharmaceuticals Meets With FDA on Morphidex® |
Jul 17, 2000
Endo Pharmaceuticals and Algos Complete Merger |
Nov 29, 1999
Algos Pharmaceutical To Merge With Endo Pharmaceuticals Holdings |
